Identification of novel influenza A virus exposures by an improved high-throughput multiplex MAGPIX platform and serum adsorption.


Journal

Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007

Informations de publication

Date de publication:
03 2020
Historique:
received: 16 07 2019
revised: 27 09 2019
accepted: 01 10 2019
pubmed: 9 11 2019
medline: 6 10 2020
entrez: 9 11 2019
Statut: ppublish

Résumé

The development of serologic assays that can rapidly assess human exposure to novel influenza viruses remains a public health need. Previously, we developed an 11-plex magnetic fluorescence microsphere immunoassay (MAGPIX) by using globular head domain recombinant hemagglutinins (rHAs) with serum adsorption using two ectodomain rHAs. We compared sera collected from two cohorts with novel influenza exposures: animal shelter staff during an A(H7N2) outbreak in New York City in 2016-2017 (n = 119 single sera) and poultry workers from a live bird market in Bangladesh in 2012-2014 (n = 29 pairs). Sera were analyzed by microneutralization (MN) assay and a 20-plex MAGPIX assay with rHAs from 19 influenza strains (11 subtypes) combined with serum adsorption using 8 rHAs from A(H1N1) and A(H3N2) viruses. Antibody responses were analyzed to determine the novel influenza virus exposure. Among persons with novel influenza virus exposures, the median fluorescence intensity (MFI) against the novel rHA from exposed influenza virus had the highest correlation with MN titers to the same viruses and could be confirmed by removal of cross-reactivity from seasonal H1/H3 rHAs following serum adsorption. Interestingly, in persons with exposures to novel influenza viruses, age and MFIs against exposed novel HA were negatively correlated, whereas in persons without exposure to novel influenza viruses, age and MFI against novel HAs were positively correlated. This 20-plex high-throughput assay with serum adsorption will be a useful tool to detect novel influenza virus infections during influenza outbreak investigations and surveillance, especially when well-paired serum samples are not available.

Sections du résumé

BACKGROUND
The development of serologic assays that can rapidly assess human exposure to novel influenza viruses remains a public health need. Previously, we developed an 11-plex magnetic fluorescence microsphere immunoassay (MAGPIX) by using globular head domain recombinant hemagglutinins (rHAs) with serum adsorption using two ectodomain rHAs.
METHODS
We compared sera collected from two cohorts with novel influenza exposures: animal shelter staff during an A(H7N2) outbreak in New York City in 2016-2017 (n = 119 single sera) and poultry workers from a live bird market in Bangladesh in 2012-2014 (n = 29 pairs). Sera were analyzed by microneutralization (MN) assay and a 20-plex MAGPIX assay with rHAs from 19 influenza strains (11 subtypes) combined with serum adsorption using 8 rHAs from A(H1N1) and A(H3N2) viruses. Antibody responses were analyzed to determine the novel influenza virus exposure.
RESULTS
Among persons with novel influenza virus exposures, the median fluorescence intensity (MFI) against the novel rHA from exposed influenza virus had the highest correlation with MN titers to the same viruses and could be confirmed by removal of cross-reactivity from seasonal H1/H3 rHAs following serum adsorption. Interestingly, in persons with exposures to novel influenza viruses, age and MFIs against exposed novel HA were negatively correlated, whereas in persons without exposure to novel influenza viruses, age and MFI against novel HAs were positively correlated.
CONCLUSIONS
This 20-plex high-throughput assay with serum adsorption will be a useful tool to detect novel influenza virus infections during influenza outbreak investigations and surveillance, especially when well-paired serum samples are not available.

Identifiants

pubmed: 31701647
doi: 10.1111/irv.12695
pmc: PMC7040970
doi:

Substances chimiques

Antibodies, Viral 0
Hemagglutinin Glycoproteins, Influenza Virus 0

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-141

Subventions

Organisme : CDC HHS
ID : 1-U01-CI000298
Pays : United States

Informations de copyright

© 2019 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.

Références

Clin Infect Dis. 2017 Nov 13;65(11):1927-1929
pubmed: 29020187
J Virol Methods. 2014 Dec;209:121-5
pubmed: 25239367
J Virol. 2014 May;88(9):4828-38
pubmed: 24522930
J Infect. 2016 Mar;72(3):369-76
pubmed: 26747013
N Engl J Med. 2009 Nov 12;361(20):1945-52
pubmed: 19745214
J Clin Microbiol. 1985 May;21(5):847-9
pubmed: 3839001
Emerg Infect Dis. 2014 May;20(5):915-7
pubmed: 24751396
J Infect Dis. 2019 May 5;219(11):1688-1696
pubmed: 30395249
Clin Microbiol Infect. 2012 Aug;18(8):797-807
pubmed: 22212116
J Infect Dis. 2018 Oct 5;218(10):1571-1581
pubmed: 29931203
J Clin Microbiol. 2011 Jun;49(6):2210-5
pubmed: 21471339
Expert Rev Anti Infect Ther. 2011 Jun;9(6):669-83
pubmed: 21692672
mSphere. 2018 Dec 12;3(6):
pubmed: 30541779
J Infect Dis. 2017 Sep 15;216(suppl_4):S555-S559
pubmed: 28934456
PLoS One. 2015 Jun 23;10(6):e0129858
pubmed: 26103163
Front Immunol. 2018 Jan 08;8:1872
pubmed: 29358933
J Virol Methods. 2017 May;243:61-67
pubmed: 28108183
PLoS One. 2018 Apr 11;13(4):e0193680
pubmed: 29641537
PLoS Curr. 2010 Mar 22;2:RRN1152
pubmed: 20352039
Clin Vaccine Immunol. 2011 Aug;18(8):1205-12
pubmed: 21653743
Influenza Other Respir Viruses. 2020 Mar;14(2):129-141
pubmed: 31701647
Influenza Other Respir Viruses. 2017 May;11(3):289-297
pubmed: 28207986
J Mol Genet Med. 2009 Dec 23;3(2):217-24
pubmed: 20076794
PLoS One. 2018 Jun 27;13(6):e0199683
pubmed: 29949635
J Virol. 2013 Nov;87(22):12433-46
pubmed: 24027325
J Clin Microbiol. 1999 Apr;37(4):937-43
pubmed: 10074505
Influenza Other Respir Viruses. 2013 Mar;7(2):211-24
pubmed: 22548725
J Infect Dis. 2013 Aug 15;208(4):554-8
pubmed: 23687225
Clin Vaccine Immunol. 2014 Aug;21(8):1054-60
pubmed: 24872516

Auteurs

Zhu-Nan Li (ZN)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Emily Cheng (E)

Battelle Memorial Institute, Columbus, OH, USA.

Eugenie Poirot (E)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
New York City Department of Health and Mental Hygiene, New York, NY, USA.

Kimberly M Weber (KM)

Battelle Memorial Institute, Columbus, OH, USA.

Paul Carney (P)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Jessie Chang (J)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Feng Liu (F)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

F Liaini Gross (FL)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Battelle Memorial Institute, Columbus, OH, USA.

Crystal Holiday (C)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Alicia Fry (A)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

James Stevens (J)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Terrence Tumpey (T)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Min Z Levine (MZ)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH